Publicité
Publicité
TSHA
Taysha Gene Therapies, Inc. Common Stock
4.97
USDSponsorisé
-0.17
-3.37%
09 janv., 15:59 UTC -5
Fermé
Après-marché
4.94
-0.03
-0.54%
TSHA Rapports sur les bénéfices
Ratio de surprise positive
TSHA a dépassé 10 des 21 dernières estimations.
48%
Prochain rapport
Date du prochain rapport
24 févr. 2026
Estimate for Q4 25 (Revenue/ EPS)
$2.10M
/-$0.09
Variation implicite de Q3 25 (Revenue/ EPS)
--
/--
Variation implicite de Q4 24 (Revenue/ EPS)
+3.95%
/+28.57%
Taysha Gene Therapies, Inc. Common Stock earnings per share and revenue
On 04 nov. 2025, TSHA reported earnings of -0.09 USD per share (EPS) for Q3 25, Inline the estimate of -0.09 USD, resulting in a 0.00% surprise. Revenue reached --, compared to an expected 1.41 million, with a -100.00% difference. The market reacted with a -4.26% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analystes forecast an EPS of -0.09 USD, with revenue projected to reach 2.10 million USD, implying an hausse of 0.00% EPS, and -- of --% in Revenue from the last quarter.
FAQ
What were Taysha Gene Therapies, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Taysha Gene Therapies, Inc. Common Stock reported EPS of -$0.09, missing estimates by 0%, and revenue of $0.00, -100% below expectations.
How did the market react to Taysha Gene Therapies, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -4.26%, changed from $4.46 before the earnings release to $4.27 the day after.
When is Taysha Gene Therapies, Inc. Common Stock expected to report next?
The next earning report is scheduled for 24 févr. 2026.
What are the forecasts for Taysha Gene Therapies, Inc. Common Stock's next earnings report?
Based on 15
analystes, Taysha Gene Therapies, Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $2.10M for Q4 2025.
Which companies are reporting earnings today?
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité